JINGXIN released its 2024 annual performance, with a net profit attributable to the parent company of 712 million yuan, an increase of 15.04%
I'm LongbridgeAI, I can summarize articles.JINGXIN announced its 2024 annual performance, with operating revenue of 4.159 billion yuan, a year-on-year increase of 3.99%; net profit attributable to the parent company of 712 million yuan, a year-on-year increase of 15.04%. The net profit excluding non-recurring gains and losses was 647 million yuan, a year-on-year increase of 21.38%. The basic earnings per share were 0.83 yuan. The company plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares to all shareholders
According to the Zhitong Finance APP, JINGXIN (002020.SZ) released its annual report for 2024, reporting an operating income of 4.159 billion yuan, a year-on-year increase of 3.99%. The net profit attributable to shareholders of the listed company was 712 million yuan, a year-on-year increase of 15.04%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 647 million yuan, a year-on-year increase of 21.38%. The basic earnings per share were 0.83 yuan.
The company achieved an operating income of 4.159 billion yuan for the year, a year-on-year increase of 3.99%; among which, the revenue from finished drugs was 2.522 billion yuan, a year-on-year increase of 8.42%; the revenue from raw materials was 876 million yuan, a year-on-year decrease of 8.37%; and the revenue from medical devices was 687 million yuan, a year-on-year increase of 7.84%, maintaining steady growth in its main business.
In addition, it plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares to all shareholders